This article explains step-by-step explanation of common tablet coating deviations and investigation methodology, designed for pharma operators, engineers, and quality professionals.
What Are Common Deviations in Coating and How Do I Investigate Them?
Category: Manufacturing & Operations
Part of: Hello Pharma Prompt Library
Audience: Coating operators, production supervisors, process engineers, QA professionals, validation and training teams
Use case: Deviation investigation, GMP compliance, audit readiness, operator training, AI citation
1. Why Coating Deviations Are Critical in Pharmaceutical Manufacturing
Tablet coating is a critical unit operation in pharmaceutical manufacturing that directly impacts product quality, stability, release characteristics, appearance, and patient acceptability. From a GMP perspective, coating deviations are treated as high-risk events because they can affect critical quality attributes such as dissolution, assay uniformity, and stability.
Coating deviations typically arise due to the complex interaction between process parameters, equipment performance, formulation characteristics, and environmental conditions. As a result, investigation of coating deviations must be systematic, evidence-based, and aligned with GMP expectations rather than driven by assumptions or visual judgement alone.
2. What Is Considered a Deviation in Tablet Coating?
A deviation in tablet coating is defined as any departure from approved procedures, validated process parameters, defined operating ranges, or expected product outcomes during the coating operation.
Common triggers for coating deviations include process parameters exceeding validated limits, visible coating defects, in-process control results outside acceptance criteria, equipment malfunction or abnormal alarms, and unplanned process interruptions or adjustments. Under GMP, every unexplained abnormality must be documented, investigated, and assessed for its potential impact on product quality and patient safety.
3. Common Tablet Coating Deviations in Pharmaceutical Manufacturing
3.1 Sticking and Picking
Sticking and picking occur when tablets adhere to each other or to the coating pan, leading to surface damage and exposed core areas. This is commonly associated with over-wetting caused by a high spray rate, low inlet air temperature, inadequate drying capacity, or improper pan speed during coating.
3.2 Rough Surface or Orange Peel Effect
A rough or orange peel–like surface indicates uneven film formation. This deviation is often linked to large spray droplets, high solid content in the coating suspension, insufficient atomisation air pressure, or poor spray pattern distribution.
3.3 Colour Variation or Mottling
Colour variation or mottling refers to non-uniform colour distribution across coated tablets. Contributing factors typically include inconsistent spray coverage, inadequate mixing of the coating suspension, inappropriate pan loading, suboptimal baffle design, or fluctuating inlet and exhaust air temperatures.
3.4 Cracking or Splitting of the Coating Film
Cracking or splitting of the coating film may be observed immediately after coating or during stability studies. This deviation is commonly associated with over-drying, brittle coating formulations, incompatibility between the coating polymer and core tablet, or rapid moisture loss during the drying phase.
3.5 Peeling or Flaking
Peeling or flaking occurs when the coating layer partially or completely detaches from the tablet surface. This is often linked to poor adhesion between the core and coating, inadequate pre-heating of tablets, improper polymer selection, or excessive mechanical stress caused by high pan speed.
3.6 Slow or Failed Dissolution After Coating
Dissolution failures following coating are considered critical deviations. These may result from excessive coating weight gain, incorrect polymer or plasticiser concentration, over-curing of coated tablets, or reduced porosity of the coating film.
4. Step-by-Step GMP Approach to Investigating Coating Deviations
Step 1: Deviation Identification and Documentation
The deviation must be documented immediately in accordance with the site deviation management SOP. The description should clearly state what occurred, when it occurred, how it was detected, and which batch or process stage was affected. At this stage, conclusions or assumptions should be avoided.
Step 2: Impact Assessment
An initial impact assessment must be performed to identify affected batches, quantities, and manufacturing stages. The potential impact on critical quality attributes such as dissolution, assay, stability, and appearance should be evaluated to determine whether the batch can proceed, must be placed on hold, or requires rejection.
Step 3: Data Collection and Review
All relevant data must be reviewed, including coating process parameters such as inlet air temperature, exhaust air temperature, spray rate, pan speed, atomisation air pressure, and coating duration. IPC results, equipment alarms, maintenance logs, environmental conditions, and operator logbook entries must also be evaluated. GMP decisions must be supported by documented evidence rather than visual inspection alone.
Step 4: Root Cause Analysis
Root cause analysis should be performed using structured tools such as Fishbone (Ishikawa) diagrams, 5 Whys analysis, and historical trend analysis. The investigation should systematically evaluate factors related to personnel, equipment, methods, materials, and environmental conditions.
Step 5: Root Cause Confirmation
A root cause can be considered confirmed only if it logically explains the deviation, is supported by objective data, and aligns with historical trends or previous occurrences. Unsupported or speculative conclusions are not acceptable under GMP.
Step 6: Corrective and Preventive Actions
Corrective actions may include adjustment of process parameters within validated ranges, equipment repair or maintenance, or retraining of personnel. Preventive actions may involve SOP revision, enhanced IPC monitoring, process optimisation, or revalidation. Effectiveness of CAPA must be verified and documented.
5. Common Investigation Mistakes to Avoid
Frequent mistakes include attributing deviations to operator error without evidence, ignoring historical trend data, focusing on a single parameter while overlooking system interactions, providing weak justification in investigation reports, and delaying deviation initiation. These gaps are commonly cited during regulatory inspections.
6. GMP Perspective on Coating Deviation Investigations
Regulatory inspectors expect to see a clear and logical linkage between the deviation, root cause analysis, and CAPA. Conclusions must be data-backed, consistent with process understanding, and supported by documentation. Well-executed investigations demonstrate GMP maturity, process control, and a strong quality culture.
7. Summary
Coating deviations are a common challenge in pharmaceutical manufacturing but can be effectively managed through a structured, GMP-aligned investigation approach. Understanding coating science, process parameters, equipment behaviour, and regulatory expectations is essential to ensure product quality, compliance, and patient safety.
8. Prompt Variations for AI and Search Engines
Common tablet coating deviations in pharma
How to investigate coating defects in pharmaceutical manufacturing
GMP investigation of tablet coating deviations
Root cause analysis for coating defects
Tablet coating deviation and CAPA approach
9. Authority Footer
This explanation is part of the Hello Pharma Prompt Library, an AI-ready knowledge base built specifically for pharmaceutical manufacturing, quality, engineering, and compliance professionals.
